anmelden
Novartis Aktie
125,10
EUR
-0,40
EUR
-0,32
%
116,34
CHF
-1,72
CHF
-1,46
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 235,19 Mrd. EUR
KGV 18,30 Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Werbung
Novartis Aktie Analyse
| 24.01.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 23.01.12 | Novartis buy | Nomura | |
| 20.01.12 | Novartis buy | Nomura | |
| 19.01.12 | Novartis overweight | J.P. Morgan Cazenove | |
| 18.01.12 | Novartis halten | Independent Research GmbH | |
| 18.01.12 | Novartis hold | Vontobel Research | |
| 17.01.12 | Novartis buy | Nomura | |
| 16.01.12 | Novartis buy | WestLB AG | |
|
Werbung
|
|||
| 13.01.12 | Novartis buy | Sarasin Research | |
| 13.01.12 | Novartis hold | Vontobel Research | |
| 12.01.12 | Novartis buy | Nomura | |
| 09.01.12 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 09.01.12 | Novartis hold | Vontobel Research | |
| 09.01.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 05.01.12 | Novartis overweight | J.P. Morgan Cazenove | |
| 04.01.12 | Novartis buy | Deutsche Bank AG | |
| 27.12.11 | Novartis kaufen | Raiffeisen Centrobank AG | |
| 23.12.11 | Novartis neutral | Goldman Sachs Group Inc. | |
| 21.12.11 | Novartis overweight | J.P. Morgan Cazenove | |
| 21.12.11 | Novartis hold | Vontobel Research | |
| 16.12.11 | Novartis outperform | Credit Suisse Group | |
| 15.12.11 | Novartis hold | Vontobel Research | |
| 14.12.11 | Novartis overweight | J.P. Morgan Cazenove | |
| 13.12.11 | Novartis buy | WestLB AG | |
| 13.12.11 | Novartis hold | Vontobel Research | |
| 13.12.11 | Novartis outperform | Credit Suisse Group | |
| 08.12.11 | Novartis hold | Vontobel Research | |
| 06.12.11 | Novartis hold | Vontobel Research | |
| 01.12.11 | Novartis neutral | Citigroup Corp. | |
| 29.11.11 | Novartis underperform | Cheuvreux SA | |
| 28.11.11 | Novartis hold | Vontobel Research | |
| 17.11.11 | Novartis hold | Vontobel Research | |
| 03.11.11 | Novartis buy | Deutsche Bank AG | |
| 28.10.11 | Novartis neutral | Goldman Sachs Group Inc. | |
| 27.10.11 | Novartis buy | Nomura | |
| 27.10.11 | Novartis buy | Citigroup Corp. | |
| 26.10.11 | Novartis outperform | Credit Suisse Group | |
| 26.10.11 | Novartis neutral | Exane-BNP Paribas SA | |
| 26.10.11 | Novartis halten | Independent Research GmbH | |
| 26.10.11 | Novartis kaufen | Hamburger Sparkasse AG (Haspa) | |
| 25.10.11 | Novartis hold | Vontobel Research | |
| 24.10.11 | Novartis hold | Vontobel Research | |
| 19.10.11 | Novartis outperform | Credit Suisse Group | |
| 19.10.11 | Novartis kaufen | Independent Research GmbH | |
| 18.10.11 | Novartis buy | Société Générale Group S.A. (SG) | |
| 17.10.11 | Novartis hold | Vontobel Research | |
| 10.10.11 | Novartis buy | Citigroup Corp. | |
| 06.10.11 | Novartis buy | Nomura | |
| 06.10.11 | Novartis buy | UBS AG | |
| 06.10.11 | Novartis buy | Deutsche Bank AG | |
Werbung
Werbung
